Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

794 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-15

Study Completion Date

2020-11-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this cross-sectional, multicenter study is to determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients who attend to sites specialized in the management of severe asthma in several countries in the AstraZeneca International Region. The prevalence of an atopic phenotype and asthma control, will also be studied.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

BRazilian Asthmatics Patients EOSinophilic Profile (BRAEOS)

NCT03925415

Severe Asthma

COMPLETED

Effects of Anti-IL5 Biological Treatments on Blood IgE Levels in Severe Asthmatic Patients

NCT04181190

Asthma Asthma; Eosinophilic

COMPLETED

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma

NCT01691521

Asthma

COMPLETED PHASE3

Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils

NCT01366521

Asthma

COMPLETED PHASE2

Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients

NCT01197794

Asthma Patients

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients attending their routine clinical visit at sites specialized in the management of severe asthma in several countries in the AstraZeneca International Region. The prevalence of an atopic phenotype and the status of asthma control, will also be studied. It is expected that this study will contribute to the understanding of severe asthma, ultimately helping to inform therapeutic decisions and addressing patients' needs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study population

Patients completing the inclusión criteria

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patient, aged 12 years or older by the time of study entry
* Patient visiting a participating center for a routine clinical appointment
* Patient is willing and able to provide a blood sample for IgE and eosinophil levels determination as part of their routine clinical visit
* Diagnosis of severe asthma for at least one year as defined by:
* Treatment with guidelines-suggested medications for Global Initiative for Asthma (3) steps 4-5 asthma
* Patients or their legal guardian, who voluntarily sign and date the informed consent form prior to study entry.

Exclusion Criteria

* Patients with a diagnosis of chronic obstructive pulmonary disease or other chronic respiratory condition beyond severe asthma
* An acute or chronic condition that, in the investigator's opinion, would limit the patient's ability to participate in this study Patients who are currently under a biologic therapy to treat their severe asthma

Eligible Sex

ALL

Accepts Healthy Volunteers

No